<DOC>
	<DOCNO>NCT00256139</DOCNO>
	<brief_summary>A multicentre , randomise , double blind , placebo control phase III study subcutaneously administer Raptiva treatment patient moderate severe psoriasis</brief_summary>
	<brief_title>CLEAR Study : Clinical Experience Acquired With Raptiva Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Plaque psoriasis cover ³10 % total BSA ( see Appendix A ) Diagnosis psoriasis least 6 month A minimum PASI score 12.0 screening ( see Appendix A ) Patients either control , intolerant contraindicate least 2 currently available systemic therapy ( e.g. , photochemotherapy ( PUVA ) , cyclosporin , corticosteroid , methotrexate , oral retinoids , MMF , thioguanine , hydroxyurea , sirolimus , azathioprine , 6 MP ) ( define `` high need '' patient ) Body weight &lt; = £120 kg 18 75 year old For woman childbearing potential , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study Willingness enter Study Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis History severe allergic anaphylactic reaction humanise monoclonal antibody fusion protein contain Ig Fc region Clinically significant psoriasis flare screen time enrollment History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) Patients undergo mandatory test screening . Patients positive HIV exclude . Pregnancy lactation WBC count &lt; 4000/mL &gt; 14,000/mL Seropositivity hepatitis B C virus Patients undergo test screening . Patients positive hepatitis B antigen hepatitis C antibody exclude . Hepatic enzymes ³3 time upper limit normal History active tuberculosis ( TB ) currently undergo treatment TB PPD test chest Xray require high risk patient ( see Appendix I ) . Patients positive PPD ( due BCG vaccination ) chest Xray exclude . Presence malignancy within past 5 year , include lymphoproliferative disorder Patients history fully resolve basal cell squamous cell skin cancer may enrol . Previous treatment Raptiva ( antiCD11a ) Diagnosis hepatic cirrhosis , regardless cause severity Serum creatinine ³2 time upper limit normal Hospital admission cardiac disease , stroke , pulmonary disease within last year History substance abuse within last 5 year Any medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug Note : Restrictions and/or direction apply follow treatment specified time period prior initial study drug administration study : Systemic therapy psoriasis ( within 28 day prior Study Day 0 ) Systemic immunosuppressive drug indication ( within 28 day prior Study Day 0 ) Topical therapy psoriasis ( within 14 day prior Study Day 0 ) Live kill virus bacteria vaccine ( within 14 day prior Study Day 0 ) Other vaccine allergy desensitisation ( recommend schedule least 14 day prior Day 0 ³3 month last injection study drug ) Other experimental drug treatment ( within 28 day five half life , whichever longer , prior Day 0 ) b Blockers , ACE inhibitor , interferon , quinidine , antimalarial drug , lithium ( clinically indicate , medication allow dosage hold constant Day 28 throughout study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>